Comprehensive Analysis of immuno oncology markers in the TME of solid tumor samples using GeoMx™ Digital Spatial Profiler (DSP) and MultiOmyx™ Hyperplexed Immunofluorescence (IF). Read more about Comprehensive Analysis of immuno oncology markers in the TME of solid tumor samples using GeoMx™ Digital Spatial Profiler (DSP) and MultiOmyx™ Hyperplexed Immunofluorescence (IF).
Co-detection of a tumor-infiltrating lymphocyte immunofluorescence (IF) panel and cytokine RNA in-situ hybridization (ISH) markers in non-small cell lung cancer (NSCLC) tumor microenvironment using combined MultiOmyx and RNAScope platforms Read more about Co-detection of a tumor-infiltrating lymphocyte immunofluorescence (IF) panel and cytokine RNA in-situ hybridization (ISH) markers in non-small cell lung cancer (NSCLC) tumor microenvironment using combined MultiOmyx and RNAScope platforms
Characterizing viral mRNA and immuno-protein expression in head and neck squamous cell carcinoma using a novel automated RNAScope™/Polaris™ integrated assay Read more about Characterizing viral mRNA and immuno-protein expression in head and neck squamous cell carcinoma using a novel automated RNAScope™/Polaris™ integrated assay
An efficient probe design algorithm for direct fusion targeting from RNA Read more about An efficient probe design algorithm for direct fusion targeting from RNA
A novel comprehensive breakpoint-targeted assay for clinically actionable RNA fusions and aberrant RNAs in solid tumors. Read more about A novel comprehensive breakpoint-targeted assay for clinically actionable RNA fusions and aberrant RNAs in solid tumors.
A comprehensive genomic profiling approach to detect functional translocations and genomic alterations in a single tube workflow Read more about A comprehensive genomic profiling approach to detect functional translocations and genomic alterations in a single tube workflow
TP53/NPM1-Mutated Acute Myeloid Leukemia as a Molecularly Distinct Disease Entity Read more about TP53/NPM1-Mutated Acute Myeloid Leukemia as a Molecularly Distinct Disease Entity
Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer Read more about Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer
Real time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC Read more about Real time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma Read more about Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma